New hope for lymphoma patients who Can't tolerate standard treatment
NCT ID NCT04189757
Summary
This study is testing a cancer drug called acalabrutinib for people with mantle cell lymphoma who had to stop a similar drug, ibrutinib, because of severe side effects. The goal is to see if acalabrutinib can control the cancer while being easier for patients to tolerate. Researchers will measure how well the cancer responds and track side effects over up to three years of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.